Skip to main content

Table 1 Patients’ characteristics (N = 49)

From: Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain

Sex  
  Male/Female 43/6
Age (years-old) 69.0 ± 6.9
Body mass index (kg/m2) 20.4 ± 4.9
Cancer (Histology)  
  Lung Cancer (Ad/SQ/SCLC/Others) 48 (26/14/4/4)
  Mesothelioma 1
Stage  
  IIB/IIIA/IIIB/IVa 1/4/7/37a
ECOG PS  
  0-1/2/3/4 28/13/5/3
Pain locationb  
  Neck-shoulder/Upper limb/Chest/Hypochondrium/Lower back/Glutaeus to thigh
  4/2/32/1/7/5
Pain causesb  
  Distant metastasis (bone)/Invasion/Pleural dissemination
  22 (17)/18/11
Duration of cancer pain (months)  
  mean ± SD 4.3 ± 4.4
  median (range) 2 (0.27–18)
Duration of controlled-release oxycodone administration (months)
  mean ± SD 2.0 ± 4.3
  median (range) 0.6 (0.1 - 19.7)
Fentanyl patch treatment site  
  day 1  
   Hospitalized/Outpatient 40/9
  day 8  
   Hospitalized/Outpatient 32/17
  day 15  
   Hospitalized/Outpatient 22/27
Concomitant systemic chemotherapy  
  Yes/No 25/24
Concomitant radiotherapy  
  Yes/No 12/37
  1. Ad, Adenocarcinoma; SQ, Squamous cell carcinoma; SCLC, Small cell lung carcinoma; ECOG PS, European Clinical Oncology Group Performance status; SD, standard deviation.
  2. aincluding a case with malignant mesothelioma in c-stage IV.
  3. bThere were two overlapping.